keyword
MENU ▼
Read by QxMD icon Read
search

second line docetaxel OS

keyword
https://www.readbyqxmd.com/read/29777823/updated-efficacy-analysis-including-secondary-population-results-for-oak-a-randomized-phase-iii-study-of-atezolizumab-vs-docetaxel-in-patients-with-previously-treated-advanced-non-small-cell-lung-cancer
#1
L Fehrenbacher, J von Pawel, K Park, A Rittmeyer, D R Gandara, S Ponce Aix, J-Y Han, S M Gadgeel, T Hida, D L Cortinovis, M Cobo, D M Kowalski, F De Marinis, M Gandhi, B Danner, C Matheny, M Kowanetz, P He, F Felizzi, H Patel, A Sandler, M Ballinger, F Barlesi
INTRODUCTION: The efficacy and safety of atezolizumab vs docetaxel as second- or third-line treatment in patients with advanced non-small cell lung cancer in the primary (n=850; ITT850) and secondary (n=1225; ITT1225) efficacy populations of the randomized phase III OAK study at an updated data cutoff were assessed. METHODS: Patients received atezolizumab 1200mg or docetaxel 75mg/m2 intravenously every 3 weeks until loss of clinical benefit or disease progression, respectively...
May 16, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29731989/statin-use-and-survival-in-patients-with-metastatic-castration-resistant-prostate-cancer-treated-with-abiraterone-or-enzalutamide-after-docetaxel-failure-the-international-retrospective-observational-staben-study
#2
Jacob A Gordon, Carlo Buonerba, Gregory Pond, Daniel Crona, Silke Gillessen, Giuseppe Lucarelli, Sabrina Rossetti, Tanya Dorff, Salvatore Artale, Jennifer A Locke, Davide Bosso, Matthew Ivan Milowsky, Mira Sofie Witek, Michele Battaglia, Sandro Pignata, Cyrus Cherhroudi, Michael E Cox, Pietro De Placido, Dario Ribera, Aurelius Omlin, Gaetano Buonocore, Kim Chi, Christian Kollmannsberger, Daniel Khalaf, Gaetano Facchini, Guru Sonpavde, Sabino De Placido, Bernhard J Eigl, Giuseppe Di Lorenzo
Background: Statins may potentiate the effects of anti-hormonal agents for metastatic castration-resistant prostate cancer (mCRPC) through further disruption of essential steroidogenic processes. We investigated the effects of statin use on clinical outcomes in patients with mCRPC receiving abiraterone or enzalutamide. Materials and methods: This was a retrospective multicenter study including patients that received abiraterone or enzalutamide for mCRPC. The effect of concurrent statin use on outcomes was evaluated...
April 13, 2018: Oncotarget
https://www.readbyqxmd.com/read/29721850/exposure-response-relationship-for-ramucirumab-from-the-randomized-double-blind-phase-3-revel-trial-docetaxel-versus-docetaxel-plus-ramucirumab-in-second-line-treatment-of-metastatic-non-small-cell-lung-cancer
#3
Egbert F Smit, Edward B Garon, Martin Reck, Federico Cappuzzo, Paolo Bidoli, Roger B Cohen, Ling Gao, Lisa M O'Brien, Pablo Lee, Annamaria Zimmermann, David R Ferry, Allen S Melemed, Maurice Pérol
PURPOSE: Ramucirumab plus docetaxel improved survival in REVEL, a randomized phase 3 trial for patients with Stage IV non-small cell lung cancer after standard platinum-based chemotherapy. This exploratory analysis evaluated the exposure-response relationship of ramucirumab from REVEL. METHODS: Patients received ramucirumab (10 mg/kg) or placebo plus docetaxel (75 mg/m2 ) every 3 weeks. Pharmacokinetic samples were collected. A population pharmacokinetic analysis predicted ramucirumab minimum concentration after first-dose administration (Cmin,1 ) and average concentration at steady state (Cave,ss )...
May 2, 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29692997/efficacy-of-next-treatment-received-after-nivolumab-progression-in-patients-with-advanced-nonsmall-cell-lung-cancer
#4
Adrien Costantini, Jennifer Corny, Vincent Fallet, Sophie Renet, Sylvie Friard, Christos Chouaid, Boris Duchemann, Etienne Giroux-Leprieur, Laurent Taillade, Ludovic Doucet, Marina Nguenang, Stéphane Jouveshomme, Marie Wislez, Jean Tredaniel, Jacques Cadranel
Nivolumab for the treatment of advanced nonsmall cell lung cancer (NSCLC) evaluated in phase III trials showed 50% progression at first evaluation, but better overall survival (OS), suggesting regained efficacy of treatments given thereafter. We aimed to evaluate the efficacy of nivolumab and of next treatment received after nivolumab progression in patients with advanced NSCLC. Our multicentre retrospective study included all patients receiving nivolumab between January and December 2015. The primary end-point was progression-free survival (PFS) of treatment given after nivolumab...
April 2018: ERJ Open Research
https://www.readbyqxmd.com/read/29688882/withdrawn-disparity-in-public-funding-of-therapies-for-metastatic-castrate-resistant-prostate-cancer-across-canadian-provinces
#5
Dixon T S Woon, Thenappan Chandrasekar, Lorne Aaron, Naveen S Basappa, Kim N Chi, Henry J Conter, Brita Danielson, Sebastien J Hotte, Shawn Malone, Fred Saad, Bobby Shayegan, Laura Park-Wyllie, Robert J Hamilton
Ahead of print article withdrawn by publisher.
April 12, 2018: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/29521649/overall-survival-results-of-the-feasibility-study-of-adjuvant-chemotherapy-with-docetaxel-plus-cisplatin-followed-by-long-term-single-agent-administration-of-s-1-in-patients-with-completely-resected-non-small-cell-lung-cancer-thoracic-oncology-research-group
#6
Seiji Niho, Norihiko Ikeda, Hiroshi Michimae, Kenji Suzuki, Hiroshi Sakai, Takayuki Kaburagi, Katsuo Yoshiya, Koichi Minato, Terufumi Kato, Hiroaki Okamoto, Takashi Seto, Yukio Hosomi, Kimihiro Shimizu, Haruhiro Saito, Masanori Tsuchida, Hideo Kunitoh, Masahiro Tsuboi, Masahiro Takeuchi, Koshiro Watanabe
OBJECTIVES: The TORG0809 study was a multicenter feasibility study of long-term single-agent therapy with S-1 after docetaxel plus cisplatin therapy in patients with completely resected stage II or stage IIIA non-small cell lung cancer. We report the results of the final overall survival (OS) analysis. PATIENTS AND METHODS: A total of 129 eligible patients received 3 cycles of docetaxel (60 mg/m, day 1) plus cisplatin (80 mg/m, day 1), followed by S-1 at 40 mg/m twice daily for 14 consecutive days, for >6 months (maximum, 1 y)...
March 7, 2018: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29500065/plasma-cell-free-dna-concentration-and-outcomes-from-taxane-therapy-in-metastatic-castration-resistant-prostate-cancer-from-two-phase-iii-trials-firstana-and-proselica
#7
Niven Mehra, David Dolling, Semini Sumanasuriya, Rossitza Christova, Lorna Pope, Suzanne Carreira, George Seed, Wei Yuan, Jane Goodall, Emma Hall, Penny Flohr, Gunther Boysen, Diletta Bianchini, Oliver Sartor, Mario A Eisenberger, Karim Fizazi, Stephane Oudard, Mustapha Chadjaa, Sandrine Macé, Johann S de Bono
BACKGROUND: Noninvasive biomarkers are needed to guide metastatic castration-resistant prostate cancer (mCRPC) treatment. OBJECTIVE: To clinically qualify baseline and on-treatment cell-free DNA (cfDNA) concentrations as biomarkers of patient outcome following taxane chemotherapy. DESIGN, SETTING, AND PARTICIPANTS: Blood for cfDNA analyses was prospectively collected from 571 mCRPC patients participating in two phase III clinical trials, FIRSTANA (NCT01308567) and PROSELICA (NCT01308580)...
February 28, 2018: European Urology
https://www.readbyqxmd.com/read/29374414/a-modified-epirubicin-and-oxaliplatin-plus-capecitabine-eox-regimen-as-a-second-line-therapy-in-patients-with-advanced-gastric-cancer
#8
Yakup Bozkaya, Nuriye Yıldırım Özdemir, Ozan Yazıcı, Nebi Serkan Demirci, Alican Kurtipek, Gökmen Umut Erdem, Yakup Ergün, Nurullah Zengin
Objective: We aimed to evaluate the effectiveness of an mEOX (modified epirubicin, oxaliplatin plus capecitabine) regimen as second line therapy after failure of mDCF (modified docetaxel, cisplatin plus fluorouracil). Methods: Gastic cancer patients for whom first-line therapy was unsuccessful and who subsequently received mEOX (epirubicin 50 mg/ m2 on day 1, oxaliplatin 85 mg/m² day 1 and capecitabine twice-daily dose of 625 mg/ m2, p.o. for 2 weeks) every 3 weeks until disease progression or unacceptable toxicity, were retrospectively analyzed...
January 27, 2018: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/29373274/efficacy-and-safety-of-ramucirumab-with-docetaxel-versus-placebo-with-docetaxel-as-second-line-treatment-of-advanced-non-small-cell-lung-cancer-a-subgroup-analysis-according-to-patient-age-in-the-revel-trial
#9
Suresh S Ramalingam, Maurice Pérol, Martin Reck, Ruben Dario Kowalyszyn, Oliver Gautschi, Martin Kimmich, Eun Kyung Cho, Grzegorz Czyzewicz, Alexandru Grigorescu, Nina Karaseva, Shaker Dakhil, Pablo Lee, Annamaria Zimmerman, Andreas Sashegyi, Ekaterine Alexandris, Gebra Cuyun Carter, Katherine B Winfree, Edward B Garon
INTRODUCTION: Ramucirumab, a recombinant human immunoglobulin G1 monoclonal antibody receptor antagonist designed to block the ligand-binding site of vascular endothelial growth factor receptor-2 (VEGFR-2), was evaluated as second-line treatment in combination with docetaxel in patients with non-small-cell lung cancer in the REVEL trial (NCT01168973). Ramucirumab significantly improved overall survival (OS) and progression-free survival (PFS). We report age subgroup analysis results primarily on the basis of a 65-year cutoff...
May 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29274813/comparison-of-alternative-androgen-receptor-axis-targeted-agent-arata-and-docetaxel-as-second-line-therapy-for-patients-with-metastatic-castration-resistant-prostate-cancer-with-progression-after-initial-arata-in-real-world-clinical-practice-in-japan
#10
Hideaki Miyake, Takayuki Sugiyama, Ryota Aki, Yuto Matsushita, Keita Tamura, Daisuke Motoyama, Toshiki Ito, Atsushi Otsuka
BACKGROUND: The objective of the present study was to assess the oncologic outcomes of patients receiving second-line therapy against metastatic castration-resistant prostate cancer (mCRPC). PATIENTS AND METHODS: The present study included 222 consecutive mCRPC patients with progression during initial androgen receptor-axis-targeted agent (ARATA) therapy with either abiraterone acetate (AA) or enzalutamide (Enz). Of these 222 patients, 108 subsequently received an alternative ARATA (AA-to-Enz, n = 49; Enz-to-AA, n = 59) and 114 received docetaxel (DTX; AA-to-DTX, n = 54; Enz-to-DTX, n = 60)...
December 6, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29191593/outcomes-in-patients-with-aggressive-or-refractory-disease-from-revel-a-randomized-phase-iii-study-of-docetaxel-with-ramucirumab-or-placebo-for-second-line-treatment-of-stage-iv-non-small-cell-lung-cancer
#11
Martin Reck, Luis Paz-Ares, Paolo Bidoli, Federico Cappuzzo, Shaker Dakhil, Denis Moro-Sibilot, Hossein Borghaei, Melissa Johnson, Robert Jotte, Nathan A Pennell, Frances A Shepherd, Anne Tsao, Michael Thomas, Gebra Cuyun Carter, Faye Chan-Diehl, Ekaterine Alexandris, Pablo Lee, Annamaria Zimmermann, Andreas Sashegyi, Maurice Pérol
OBJECTIVES: The REVEL study demonstrated improved efficacy for patients with advanced non-small cell lung cancer treated with ramucirumab plus docetaxel, independent of histology. This exploratory analysis characterized the treatment effect in REVEL patients who were refractory to prior first-line treatment. MATERIALS AND METHODS: Refractory patients had a best response of progressive disease to first-line treatment. Endpoints included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), quality of life (QoL), and safety...
October 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29082855/comparative-efficacy-and-safety-of-second-line-treatments-for-advanced-non-small-cell-lung-cancer-with-wild-type-or-unknown-status-for-epidermal-growth-factor-receptor-a-systematic-review-and-network-meta-analysis
#12
REVIEW
Perrine Créquit, Anna Chaimani, Amélie Yavchitz, Nassima Attiche, Jacques Cadranel, Ludovic Trinquart, Philippe Ravaud
BACKGROUND: Docetaxel, pemetrexed, erlotinib, and gefitinib are recommended as second-line treatment for advanced non-small cell lung cancer (NSCLC) with wild-type or unknown status for epidermal growth factor receptor (EGFR). However, the number of published randomized clinical trials (RCTs) on this topic is increasing. Our objective was to assess the comparative effectiveness and tolerability of all second-line treatments for advanced NSCLC with wild-type or unknown status for EGFR by a systematic review and network meta-analysis...
October 30, 2017: BMC Medicine
https://www.readbyqxmd.com/read/29045938/effectiveness-of-nivolumab-versus-docetaxel-as-second-line-treatment-in-non-small-cell-lung-cancer-patients-in-clinical-practice
#13
Pablo Calpe-Armero, Rafael Ferriols-Lisart, Francisco Ferriols-Lisart, Alejandro Pérez-Pitarch
AIMS: To evaluate the effectiveness of nivolumab as second-line treatment compared to standard therapy with docetaxel in adult patients with non-small cell lung cancer (NSCLC) in clinical practice. METHODS: This is an observational, retrospective cohort study of adult patients diagnosed with NSCLC, stage III-IV, treated with docetaxel or nivolumab as second-line treatment. The end points evaluated were overall survival (OS) and progression-free survival (PFS). PFS and OS were described using the Kaplan-Meier method...
2017: Chemotherapy
https://www.readbyqxmd.com/read/29045535/select-2-a-phase-ii-double-blind-randomized-placebo-controlled-study-to-assess-the-efficacy-of-selumetinib-plus-docetaxel-as-a-second-line-treatment-of-patients-with-advanced-or-metastatic-non-small-cell-lung-cancer
#14
J-C Soria, A Fülöp, C Maciel, J R Fischer, G Girotto, S Lago, E Smit, G Ostoros, W E E Eberhardt, P Lishkovska, S Lovick, G Mariani, A McKeown, E Kilgour, P Smith, K Bowen, A Kohlmann, D J Carlile, P A Jänne
Background: Combination of selumetinib plus docetaxel provided clinical benefit in a previous phase II trial for patients with KRAS-mutant advanced non-small-cell lung cancer (NSCLC). The phase II SELECT-2 trial investigated safety and efficacy of selumetinib plus docetaxel for patients with advanced or metastatic NSCLC. Patients and methods: Patients who had disease progression after first-line anti-cancer therapy were randomized (2 : 2 : 1) to selumetinib 75 mg b...
December 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28938671/pd-1-pd-l1-antibodies-efficacy-and-safety-versus-docetaxel-monotherapy-in-advanced-nsclc-patients-after-first-line-treatment-option-systems-assessment
#15
Qiang Su, Zhigang Sun, Chenguang Zhang, Yanli Hou, Bangwei Cao
Meta-analysis was conducted to systematically assess the effectiveness and safety of programmed cell death protein-1 or ligand-1 (PD-1 or PD-L1) antibodies versus docetaxel alone in advanced non small cell lung cancer (NSCLC). In addition, the prognostic significance of PD-L1 expression in advanced NSCLC was also investigated. 5 eligible studies including 3579 patients were identified through comprehensive search of multiple databases. The results showed that pooled hazard ratios (HR) for overall survival (OS) and progression free survival (PFS) were 0...
August 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/28934120/angiogenesis-inhibitors-in-nsclc
#16
REVIEW
Anna Manzo, Agnese Montanino, Guido Carillio, Raffaele Costanzo, Claudia Sandomenico, Nicola Normanno, Maria Carmela Piccirillo, Gennaro Daniele, Francesco Perrone, Gaetano Rocco, Alessandro Morabito
Angiogenesis is a complex biological process that plays a relevant role in sustaining the microenvironment, growth, and metastatic potential of several tumors, including non-small cell lung cancer (NSCLC). Bevacizumab was the first angiogenesis inhibitor approved for the treatment of patients with advanced NSCLC in combination with chemotherapy; however, it was limited to patients with non-squamous histology and first-line setting. Approval was based on the results of two phase III trials (ECOG4599 and AVAIL) that demonstrated an improvement of about two months in progression-free survival (PFS) in both trials, and in the ECOG4599 trial, an improvement in overall survival (OS) also...
September 21, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28835513/fda-approval-summary-pembrolizumab-for-treatment-of-metastatic-non-small-cell-lung-cancer-first-line-therapy-and-beyond
#17
Lee Pai-Scherf, Gideon M Blumenthal, Hongshan Li, Sriram Subramaniam, Pallavi S Mishra-Kalyani, Kun He, Hong Zhao, Jingyu Yu, Mark Paciga, Kirsten B Goldberg, Amy E McKee, Patricia Keegan, Richard Pazdur
On October 24, 2016, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda; Merck & Co., Inc., https://www.merck.com) for treatment of patients with metastatic non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1) as determined by an FDA-approved test, as follows: (a) first-line treatment of patients with mNSCLC whose tumors have high PD-L1 expression (tumor proportion score [TPS] ≥50%), with no epidermal growth factor receptor ( EGFR ) or anaplastic lymphoma kinase ( ALK ) genomic tumor aberrations, and (b) treatment of patients with mNSCLC whose tumors express PD-L1 (TPS ≥1%), with disease progression on or after platinum-containing chemotherapy...
November 2017: Oncologist
https://www.readbyqxmd.com/read/28826931/comparison-of-sequential-treatment-with-androgen-receptor-targeted-agent-followed-by-another-androgen-receptor-targeted-agent-versus-androgen-receptor-targeted-agent-followed-by-docetaxel-in-chemotherapy-naive-patients-with-metastatic-castration-resistant-prostate
#18
Nobuaki Matsubara, Yoko Yamada, Ken-Ichi Tabata, Takefumi Satoh, Naoto Kamiya, Hiroyoshi Suzuki, Takashi Kawahara, Hiroji Uemura, Akihiro Yano, Satoru Kawakami, Masafumi Otsuka, Satoshi Fukasawa
BACKGROUND: An important clinical question of great interest to clinicians is how to best sequence androgen receptor targeted agents (ARTAs) and chemotherapy for metastatic castration-resistant prostate cancer (mCRPC), but the answer is still unclear. MATERIALS AND METHODS: To evaluate and compare the clinical outcomes of ARTA and docetaxel (DTX) as second-line treatment in the post first-line ARTA, we conducted a retrospective analysis of chemotherapy-naive mCRPC patients who had received sequential treatment with ARTA followed by another ARTA (ARTA-ARTA) or ARTA followed by DTX (ARTA-DTX)...
December 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28818987/response-assessment-of-68-ga-dota-e-c-rgdfk-2-pet-ct-in-lung-adenocarcinoma-patients-treated-with-nintedanib-plus-docetaxel
#19
Oscar Arrieta, Francisco O Garcia-Perez, David Michel-Tello, Laura-Alejandra Ramírez-Tirado, Quetzali Pitalua-Cortes, Graciela Cruz-Rico, Eleazar-Omar Macedo-Pérez, Andrés F Cardona, Jaime de la Garza-Salazar
Nintedanib is an oral angiokinase inhibitor used as second-line treatment for non-small cell lung cancer. New radiotracers, such as 68 Ga-DOTA-E-[c(RGDfK)]2 , that target αv β3 integrin might have an impact as a noninvasive method for assessing angiogenesis inhibitors. Methods: From July 2011 through October 2015, 38 patients received second-line nintedanib plus docetaxel. All patients underwent PET/CT with 68 Ga-DOTA-E-[c(RGDfK)]2 radiotracer and blood-sample tests to quantify angiogenesis factors (fibroblast growth factor, vascular endothelial growth factor, and platelet-derived growth factor AB) before and after completing 2 therapy cycles...
March 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28795333/patient-characteristics-and-overall-survival-in-patients-with-post-docetaxel-metastatic-castration-resistant-prostate-cancer-in-the-community-setting
#20
William K Oh, Raymond Miao, Francis Vekeman, Jennifer Sung, Wendy Y Cheng, Marjolaine Gauthier-Loiselle, Ravinder Dhawan, Mei Sheng Duh
It is unclear how treatment sequencing for metastatic castration-resistant prostate cancer (mCRPC) affects real-world patient outcomes. We assessed treatment sequences, patient characteristics and overall survival (OS) in post-docetaxel mCRPC patients. mCRPC patients receiving second-line cabazitaxel or androgen receptor-targeted therapy (ART; abiraterone/enzalutamide) post-docetaxel were identified using electronic medical records. OS was assessed from second-line therapy initiation using Cox regressions adjusting for: metastases; prostate-specific antigen (PSA); hemoglobin; alkaline phosphatase (ALP); albumin; second-line therapy initiation year...
August 10, 2017: Medical Oncology
keyword
keyword
79959
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"